60. 再生不良性貧血 Aplastic anemia Clinical trials / Disease details
臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100045322 | 2021-06-01 | 2021-04-12 | Efficacy and safety of umbilical cord mesenchymal stem cells combined with standard immunosuppressive agents in the treatment of children with acquired severe aplastic anemia: a randomized, controlled clinical study | Efficacy and safety of umbilical cord mesenchymal stem cells combined with standard immunosuppressive agents in the treatment of children with acquired severe aplastic anemia: a randomized, controlled clinical study | pediatric acquired severe aplastic anemia | Experimental group:Anti-thymocyte globulin+Ciclosporin A+Mesenchymal stem cell;Control group:Anti-thymocyte globulin+Ciclosporin A; | Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Sciences | NULL | Recruiting | 1 | 16 | Both | Experimental group:32;Control group:32; | China | |
| 2 | ChiCTR1900026462 | 2019-08-19 | 2019-10-11 | Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cells co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia | Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cell co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia--single-center, single-arm, open clinical study | aplastic anemia,AA | Cass series:low dose post Cyclophosphamide and Mesenchymal stem cell; | Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital | NULL | Recruiting | Both | Cass series:20; | China | |||
| 3 | NCT03055078 (ClinicalTrials.gov) | January 2017 | 4/2/2017 | Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia | Evaluation of Safety and Efficacy in Patients With Aplastic Anemia by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells | Aplastic Anemia | Biological: mesenchymal stem cells | Hebei Medical University | NULL | Recruiting | 14 Years | 60 Years | All | 10 | Phase 1 | China |
| 4 | NCT02407470 (ClinicalTrials.gov) | January 2015 | 25/3/2015 | Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia | A Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Rabbit antithymoglobulin (ATG);Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs);Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs) | Navy General Hospital, Beijing | Peking Union Medical College Hospital;General Hospital of Beijing PLA Military Region;Chinese Academy of Medical Sciences | Recruiting | 14 Years | 70 Years | Both | 90 | Phase 1/Phase 2 | China |
| 5 | NCT02218437 (ClinicalTrials.gov) | October 2013 | 6/8/2014 | Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) | Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells. | Complications of Organ Transplant Stem Cells Umbilical Cord | Drug: MSC+ATG | Chinese Academy of Medical Sciences | NULL | Recruiting | 1 Month | 18 Years | Both | 20 | Phase 4 | China |
| 6 | NCT02247973 (ClinicalTrials.gov) | February 2013 | 17/9/2014 | Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. | Phase?Trial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia. | Severe Aplastic Anemia | Biological: mesenchymal stem cells | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First Municipal People’s Hospital;Nanfang Hospital of Southern Medical University;Southern Medical University, China;First Affiliated Hospital, Sun Yat-Sen University;Second Affiliated Hospital, Sun Yat-Sen University;Third Affiliated Hospital, Sun Yat-Sen University;Fifth Affiliated Hospital, Sun Yat-Sen University;Guangdong General Hospital;The Second People's Hospital of GuangDong Province;First Affiliated Hospital of Jinan University;The First Affiliated Hospital of Guangzhou Medical University;Second Affiliated Hospital of Guangzhou Medical University;Peking University Shenzhen Hospital;Shenzhen Second People's Hospital | Enrolling by invitation | 14 Years | 50 Years | Both | 100 | Phase 2 | China |
| 7 | NCT01305694 (ClinicalTrials.gov) | February 2011 | 28/2/2011 | Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. | Phase?/?Trial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia. | Aplastic Anemia | Biological: bone marrow derived mesenchymal stem cells | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou Municipal Twelfth People's Hospital;Guangdong Prevention and Treatment Center for Occupational Diseases | Recruiting | 16 Years | N/A | Both | 50 | Phase 1/Phase 2 | China |
| 8 | NCT01297972 (ClinicalTrials.gov) | February 2011 | 16/2/2011 | Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia | Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia | Aplastic Anemia | Biological: Intravenous bone marrow mesenchymal stem cells infusion | University of Sao Paulo | NULL | Completed | 18 Years | 65 Years | Both | 9 | Phase 1/Phase 2 | Brazil |
| 9 | EUCTR2008-005594-35-BE (EUCTR) | 28/10/2009 | 06/08/2009 | Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre study. - NA | Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre study. - NA | Hematological disorders of the following types:ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse).AML: acute myelocytic leukemia in remission (excluding relapse).CML: chronic myelocytic leukemia who are in the chronic phase of the disease.Severe aplastic anemia, hemoglobinopathies (thalassemia major).Inborn errors of metabolism.Myelodysplastic syndromes MedDRA version: 9.1;Level: LLT;Classification code 10027703;Term: Mismatched donor bone marrow transplantation therapy | Product Name: Mesenchymal stem cells Product Code: MSC | CHU Sart-Tilman | NULL | Not Recruiting | Female: yes Male: yes | 172 | Phase 3 | Belgium |